Randi Hagerman
Medical Director
MIND Institute
From this contributor
Diabetes drug delivers multiple benefits for people with fragile X syndrome
Researcher Randi Hagerman is a big proponent of metformin — a diabetes drug that she is testing in people with fragile X syndrome. In fact, Hagerman takes the drug herself as a preventive measure against cancer.
Diabetes drug delivers multiple benefits for people with fragile X syndrome
Drug trials for fragile X syndrome lead the way for autism
Several targeted trials on drugs that treat fragile X syndrome are under way. But accurate endpoints to measure the drugs’ effectiveness are crucial, argues developmental and behavioral pediatrician Randi Hagerman.
Drug trials for fragile X syndrome lead the way for autism
Explore more from The Transmitter
Links between tuberous sclerosis complex and autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 August.
Links between tuberous sclerosis complex and autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 August.
The fun and flexibility of data science
Taylor Bolt spent his Ph.D. and postdoc digging through brain imaging data for clues to cognition. In industry, the datasets are different but the joy of answering questions with data remains.
The fun and flexibility of data science
Taylor Bolt spent his Ph.D. and postdoc digging through brain imaging data for clues to cognition. In industry, the datasets are different but the joy of answering questions with data remains.
Mind over metrics: How can we tell if two brains (or AI models) are alike?
The ability to record from large populations of neurons has triggered the development of myriad methods for comparing them. But we’re still grappling with how to convert measures of likeness into a better mechanistic understanding.
Mind over metrics: How can we tell if two brains (or AI models) are alike?
The ability to record from large populations of neurons has triggered the development of myriad methods for comparing them. But we’re still grappling with how to convert measures of likeness into a better mechanistic understanding.